Author/Editor     Čučnik, S; Kveder, T; Ulcova-Gallova, Z; Swadzba, J; Musial, J; Valesini, G; Avčin, T; Rozman, B; Božič, B
Title     Avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies
Type     članek
Source     Lupus
Vol. and No.     Letnik 20, št. 11
Publication year     2011
Volume     str. 1166-71
Language     eng
Abstract     Objective. The objective of this study was to extend the findings of the preliminary study by measuring the avidity of IgG anti-beta2-glycoprotein I antibodies (anti-beta2-GPI) on a larger group of patients with primary or secondary antiphospholipid syndrome (APS) and anti-beta2-GPI positive patients without APS in the frame of the European Forum on antiphospholipid antibodies (aPL). Methods. Serum from 137 patients with primary APS, APS associated with autoimmune diseases, and patients with autoimmune diseases other than APS from five EU rheumatology centres were tested for anti-beta2-GPI antibodies. The 109 patients who were sera positive for anti-beta2-GPI by the in-house anti-beta2-GPI enzyme-linked immunosorbent assay (ELISA) at the Immunology Laboratory, UMC Ljubljana were selected for further testing on avidity with chaotropic anti-beta2-GPI ELISA. Results. High, low and heterogeneous avidity IgG anti-beta2-GPI was found in 32/109, 17/109 and 60/109 patients respectively. Significantly more patients with APS were in the high avidity than in the low avidity anti-beta2-GPI group, while the opposite was observed for non-APS (both p < 0.001). The most common clinical feature among patients with high avidity anti-beta2-GPI was thrombosis, mainly due to venous thrombosis (p < 0.01 and p < 0.001, versus low avidity anti-beta2-GPI group). Conclusion. Patients with or without APS had anti-beta2-GPI of high, low or heterogeneous avidity. High avidity anti-beta2-GPI was associated with thrombosis and APS, while in the low avidity anti-beta2-GPI group non-APS (predominantly SLE) patients prevailed. Determination of anti-beta2-GPI avidity should be considered in the analytical strategies for further differentiation of patients with anti-beta2-GPI antibodies.
Descriptors     ANTIPHOSPHOLIPID SYNDROME
ANTIBODIES, ANTIPHOSPHOLIPID
GLYCOPROTEINS
IGG
THROMBOSIS
MULTICENTER STUDIES
EUROPE